CTLA4 and neoplasm: Anti-CTLA-4 monoclonal antibodies (mAb) further induce potent anti-tumor effects by depleting CTLA-4-expressing Treg cells within the tumor microenvironment (TME) through Ab-dependent cytotoxic activity (ADCC).